Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A comparative, placebo-controlled, double blind, double dummy, cross-over, single centre, phase IIIb study between formoterol alone (Oxis (Rm) Turbuhaler (Rm) 4.5 microg) and the fixed combination of formoterol and budesonide (Symbicort (Rm) Turbuhaler (Rm) 160/4.5 microg) on airway responsiveness and airway inflammation induced by repeated low-dose allergen challenge in allergic patients with mild asthma.

X
Trial Profile

A comparative, placebo-controlled, double blind, double dummy, cross-over, single centre, phase IIIb study between formoterol alone (Oxis (Rm) Turbuhaler (Rm) 4.5 microg) and the fixed combination of formoterol and budesonide (Symbicort (Rm) Turbuhaler (Rm) 160/4.5 microg) on airway responsiveness and airway inflammation induced by repeated low-dose allergen challenge in allergic patients with mild asthma.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 03 Feb 2011

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Budesonide/formoterol (Primary) ; Formoterol
  • Indications Allergic asthma; Asthma
  • Focus Pharmacodynamics; Therapeutic Use
  • Acronyms SMILDA
  • Most Recent Events

    • 01 Apr 2009 Results reported in the European Respiratory Journal.
    • 29 Mar 2006 New trial record.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top